Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors.
Dierynck I, Van Marck H, Van Ginderen M, Jonckers TH, Nalam MN, Schiffer CA, Raoof A, Kraus G, Picchio G. Dierynck I, et al. Among authors: van ginderen m. Antimicrob Agents Chemother. 2011 Dec;55(12):5723-31. doi: 10.1128/AAC.00748-11. Epub 2011 Sep 6. Antimicrob Agents Chemother. 2011. PMID: 21896904 Free PMC article.
Indolopyridones inhibit human immunodeficiency virus reverse transcriptase with a novel mechanism of action.
Jochmans D, Deval J, Kesteleyn B, Van Marck H, Bettens E, De Baere I, Dehertogh P, Ivens T, Van Ginderen M, Van Schoubroeck B, Ehteshami M, Wigerinck P, Götte M, Hertogs K. Jochmans D, et al. Among authors: van ginderen m. J Virol. 2006 Dec;80(24):12283-92. doi: 10.1128/JVI.00889-06. Epub 2006 Oct 4. J Virol. 2006. PMID: 17020946 Free PMC article.
Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors.
Goethals O, Clayton R, Van Ginderen M, Vereycken I, Wagemans E, Geluykens P, Dockx K, Strijbos R, Smits V, Vos A, Meersseman G, Jochmans D, Vermeire K, Schols D, Hallenberger S, Hertogs K. Goethals O, et al. Among authors: van ginderen m. J Virol. 2008 Nov;82(21):10366-74. doi: 10.1128/JVI.00470-08. Epub 2008 Aug 20. J Virol. 2008. PMID: 18715920 Free PMC article.
Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles.
Goethals O, Vos A, Van Ginderen M, Geluykens P, Smits V, Schols D, Hertogs K, Clayton R. Goethals O, et al. Among authors: van ginderen m. Virology. 2010 Jul 5;402(2):338-46. doi: 10.1016/j.virol.2010.03.034. Epub 2010 Apr 24. Virology. 2010. PMID: 20421122 Free article.
Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor.
Goethals O, Van Ginderen M, Vos A, Cummings MD, Van Der Borght K, Van Wesenbeeck L, Feyaerts M, Verheyen A, Smits V, Van Loock M, Hertogs K, Schols D, Clayton RF. Goethals O, et al. Among authors: van ginderen m. Antiviral Res. 2011 Aug;91(2):167-76. doi: 10.1016/j.antiviral.2011.05.011. Epub 2011 Jun 12. Antiviral Res. 2011. PMID: 21669228
Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein.
Roymans D, De Bondt HL, Arnoult E, Geluykens P, Gevers T, Van Ginderen M, Verheyen N, Kim H, Willebrords R, Bonfanti JF, Bruinzeel W, Cummings MD, van Vlijmen H, Andries K. Roymans D, et al. Among authors: van ginderen m. Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):308-13. doi: 10.1073/pnas.0910108106. Epub 2009 Dec 4. Proc Natl Acad Sci U S A. 2010. PMID: 19966279 Free PMC article.
JNJ-7184, a respiratory syncytial virus inhibitor targeting the connector domain of the viral polymerase.
Bonneux B, Shareef A, Tcherniuk S, Anson B, de Bruyn S, Verheyen N, Thys K, Conceição-Neto N, Van Ginderen M, Kwanten L, Ysebaert N, Vranckx L, Peeters E, Lanckacker E, Gallup JM, Sitthicharoenchai P, Alnajjar S, Ackermann MR, Adhikary S, Bhaumik A, Patrick A, Fung A, Sutto-Ortiz P, Decroly E, Mason SW, Lançois D, Deval J, Jin Z, Eléouët JF, Fearns R, Koul A, Roymans D, Rigaux P, Herschke F. Bonneux B, et al. Among authors: van ginderen m. Antiviral Res. 2024 May 19;227:105907. doi: 10.1016/j.antiviral.2024.105907. Online ahead of print. Antiviral Res. 2024. PMID: 38772503